The study found that treating women with HER2 positive metastatic breast cancer with trastuzumab deruxtecan significantly prolongs the length of time the disease is controlled and cancer growth is halted. Patients who received the drug had a 72% improvement in progression-free survival compared to trastuzumab emtansine.
A study from Joslin Diabetes Center reveals insulin resistance in non-diabetic individuals is caused by complex cell-specific signaling defects. The research also found sex-specific differences in these defects, which could serve as novel targets for therapies.
A clinical trial found that over half of patients with non-small cell lung cancer (NSCLC) with a HER2 gene mutation had their tumors stop growing or shrink after treatment with trastuzumab deruxtecan. The drug showed durable responses in 54.9% of patients, with median survival period of 17.8 months.
A new photocatalysis-membrane coupling system removes membrane fouling by generating reactive oxygen species on a separate unit, reducing the need for H2O2 transportation. This approach improves photocatalyst engineering and offers sustainable foulant control in large-scale applications.
The KEYNOTE-826 study found that adding immunotherapy to standard first-line treatment increases overall survival by eight months for patients with recurrent, persistent or metastatic cervical cancer. The addition of pembrolizumab to chemotherapy also reduced the risk of death and disease progression by 33%.
The KEYNOTE-716 trial shows that adjuvant pembrolizumab significantly prolongs recurrence-free survival and halves distant recurrences in stage II B/C melanoma patients. This suggests that patients with high-risk stage II melanoma should be offered adjuvant therapy.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.